Clinical Trials Search
Clinical Trial 19177
Interventions:AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza); Paraplatin (carboplatin); carboplatin; cisplatin; etoposide
Study Type: Treatment
Phase of Study: Phase II
- Alberto Chiappori
A Phase II Study of Olaparib Plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer
The purpose of this study is to test two things: (1) Compare any good and bad effects of using cediranib with the usual chemotherapy for SCLC (carboplatin/cisplatin and etoposide) (2) Compare any good and bad effects of adding olaparib and cediranib after the completion of chemotherapy (what is called maintenance therapy) to the usual method, which is no maintenance therapy after completion of chemotherapy.
To determine whether the addition of cediranib plus olaparib as maintenance therapy in small cell lung cancer (SCLC) leads to improved progression-free survival (PFS) compared to standard therapy (no maintenance treatment) utilizing RECIST version 1.1 criteria.